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Abstract
Introduction: In accordance with global testing and treatment targets, many countries are seeking ways to reach the “90-90-
90” goals, starting with diagnosing 90% of all people with HIV. Quality HIV testing services are needed to enable people with
HIV to be diagnosed and linked to treatment as early as possible. It is essential that opportunities to reach people with
undiagnosed HIV are not missed, diagnoses are correct and HIV-negative individuals are not inadvertently initiated on life-
long treatment. We conducted this systematic review to assess the magnitude of misdiagnosis and to describe poor HIV
testing practices using rapid diagnostic tests.
Methods: We systematically searched peer-reviewed articles, abstracts and grey literature published from 1 January 1990 to
19 April 2017. Studies were included if they used at least two rapid diagnostic tests and reported on HIV misdiagnosis, factors
related to potential misdiagnosis or described quality issues and errors related to HIV testing.
Results: Sixty-four studies were included in this review. A small proportion of false positive (median 3.1%, interquartile range
(IQR): 0.4-5.2%) and false negative (median: 0.4%, IQR: 0-3.9%) diagnoses were identified. Suboptimal testing strategies were
the most common factor in studies reporting misdiagnoses, particularly false positive diagnoses due to using a “tiebreaker”
test to resolve discrepant test results. A substantial proportion of false negative diagnoses were related to retesting among
people on antiretroviral therapy.
Conclusions: HIV testing errors and poor practices, particularly those resulting in false positive or false negative diagnoses, do
occur but are preventable. Efforts to accelerate HIV diagnosis and linkage to treatment should be complemented by efforts
to improve the quality of HIV testing services and strengthen the quality management systems, particularly the use of
validated testing algorithms and strategies, retesting people diagnosed with HIV before initiating treatment and providing
clear messages to people with HIV on treatment on the risk of a “false negative” test result.
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Introduction
In the last decade, HIV testing services have been scaled-up
substantially. In 2005, it was estimated that only 12% of
people who wanted an HIV test were able to access test-
ing; and that only 10% of people with HIV in Africa knew
their status [1]. In contrast, between 2010 and 2014, more
than 600 million people in 122 low- and middle-income coun-
tries received HIV testing [2], and as of 2015, approximately
60% of people with HIV were aware of their status [3]. Such
scale-up has been possible through the expansion of provider-
initiated testing and counselling and community-based testing
programmes, which have routinized HIV testing and extended
services to many people.
Rapid diagnostic tests (RDTs) have been instrumental to the
scale-up of HIV testing, particularly in resource-limited set-
tings where access to laboratory services is poor. RDTs have
been shown to be highly accurate and can often provide a
same-day diagnosis when used within a validated testing
strategy (i.e. the order in which the tests are performed)
and algorithm (i.e. the exact tests used within the testing
strategy) according to high (≥5%) and low HIV prevalence
(<5%), as recommended by the World Health Organization
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(WHO) [4–6]. Recent reports, however, have shown that HIV
testing is not always conducted appropriately [7,8], and in
some countries, quality systems have not kept pace with
testing scale-up. According to a review of national HIV testing
policies, less than 20% of testing strategies were consistent
withWHO guidance, and only two included recommendations
on retesting prior to the initiation of antiretroviral therapy
(ART) [9]. In some cases, poor-quality testing has resulted in
incorrect test results and the misdiagnosis of HIV status
[10–14].
HIV misdiagnosis refers to any testing event where a diag-
nosis is missed, inappropriately delayed or incorrect (either
false positive or false negative) [15]. Poor-quality HIV testing
and misdiagnosis have negative consequences for individuals,
families, communities, health workers and health services.
False negative diagnoses represent missed opportunities to
identify an HIV infection and link people to early treatment.
False positive diagnosesmay cause social and emotional harm
and create mistrust of health workers and the test results they
deliver. Without addressing HIV testing quality, new guidance
offering same-day treatment to all people diagnosed with HIV
[16] could lead to inappropriate ART initiation [11]. Once
individuals are on treatment, because ART reduces antibody
production and can cause seroreversion, for example, false
negative test results, determining a person’s true HIV status
can be especially challenging [17,18].
We conducted this systematic review to assess the mag-
nitude of misdiagnosis and to identify and describe poor
HIV testing practices using RDTs, including those which may
have led to incorrect test results and misdiagnosis.
Methods
We systematically searched for peer-reviewed articles pub-
lished from 1 January 1990 to 19 April 2017 using a predefined
search strategy in the following electronic databases: PubMed,
CINAHL and EMBASE. All conferences of the International AIDS
Society were searched from July 2001 through July 2016; the
most recent Conference on Retroviruses and Opportunistic
Infections (2014–2017) database were searched because past
conference abstracts were unavailable. Conferences of the
African Society of Laboratory Medicine (ASLM) were searched
2012–2016, as well as the ASLM website and other key global
health websites (see supplementary information). We
searched reference lists to identify additional literature. This
process was repeated until no new citations were identified.
Experts were also contacted to identify additional reports. No
geographic restrictions were placed on the search, but the
review was limited to studies published in English.
Studies were eligible if they used at least two RDTs and
reported on HIV misdiagnosis, factors related to potential
misdiagnosis or described quality issues and related to HIV
testing error.
Initial titles were screened by one investigator (VF) to
determine eligibility. A second and a third screening was
then carried out (VF, ST and CJ). All differences were
resolved through consensus. Data from all sources were
extracted and placed into standardized forms and verified
in duplicate (VF and ST). CJ and NF assessed study quality
(see supplementary data).
Potential factors relating to misdiagnosis were
extracted from studies using defined categories: (a) cle-
rical error (error in documenting and reporting informa-
tion essential to a correct status); (b) user error
(operator error collecting specimen, performing an HIV
RDT or interpreting the result); (c) suboptimal testing
strategy (errors related to the order in which specific
RDTs are used, also known as a testing strategy); (d)
poor management and supervision (lack of active quality
management systems); (e) weak reactive results (faint
lines appearing on test strips); and (f) additional factors
including cross-reactivity, acute/early infection and test-
ing among people on ART.
Other summary measures included: misdiagnosis rates (total
number of false positive diagnoses reported over the total
number of HIV-positive tests retested and reported using a
specific testing algorithm and the total number of false negative
diagnoses reported over the number of HIV-negative tests
retested and reported using a specific testing algorithm). For
studies exclusively among people diagnosedwith HIV, reporting
on false positive statuses, the total study population was used
as the denominator.
For each study, rates of diagnostic error and misdiagnosis
and corresponding 95% confidence intervals (CIs) were
calculated, using Wilson’s approach, and this was displayed
graphically using forest plots [19–21]. All statistical analyses
were conducted in STATA v13.0.
Results
Sixty-four studies reporting on misdiagnosis of HIV and
factors potentially related to misdiagnosis were included
in this review (Figure 1 and Table 1).
Most studies were carried out in Africa (n = 48) [5,7,10–
14,16,22–25,29,30,32–34,36,37,39,41,43,44,46,47,49,51,52,
54–59,61–65,67–72,74,75], followed by in the Americas
(n = 7) [28,31,42,50,53,60,66], Asia (n = 4) [8,35,45,73]
and Europe (n = 1) [48]. There were also four multi-coun-
try/regional studies [26,27,38,40]. Samples varied by size
and unit of measurement, including clients (n = 38 studies,
range: 303,010 to 1 clients), specimens (n = 15 studies,
range: 9419 to 16 specimens), health workers performing
HIV tests (n = 5 studies, range: 3835 to 39 personnel) and
sites where HIV testing was performed (n = 12 studies,
range: 602 to 4 sites). Nine studies reported more than
one unit of measure, and three studies did not specify
sample size (see supplementary information). The majority
of studies occurred in a facility-based setting; studies car-
ried out in community settings included the workplace
(n = 1) [57], home-based testing (n = 2) [14,39] and a
mobile setting (n = 1) [32].
Factors related to the quality of HIV testing and potential
misdiagnosis
Several factors, including HIV testing errors, were reported
frequently (n = 131 times) across all included studies (see
Table 2).
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Thirty-seven studies reported using a suboptimal testing
strategy that differed from the WHO recommendations
[5,8,11–14,16,22–30,32–34,36–39,42–44,49,51,53,59,62,64
–66,68,72,75]. Suboptimal testing strategies included using
a highly specific first-line test and highly sensitive second-
line test [14,33,39,55], using a single RDT for HIV-positive
diagnoses [11,66,72], using a high prevalence testing strat-
egy in a low prevalence setting [16,49], using a parallel
testing algorithms and a tiebreaker testing strategy
(where a third assay is used to resolve discrepant test
results and rule in HIV infection) [5,12,13,16,24,25,27–
30,32,34,36,37,68].
User errors, incorrectly performing the test procedure or
incorrectly interpreting results, defined as human errors, were
reported in 25 studies [7,8,11,14,26–28,31,33,34,
37,40,42,46,52,54,57,60,65–68,70,72,73]. Errors identified
included users having difficulty with specimen collection
[14,28,68], performing RDTs [31,73], interpreting test results
[10,24,27,30,32,40,42,48,62,65,66,74], reading test results
too early [7] and not using the correct reagents/buffer [7].
Twenty-one studies reported inadequate management
and supervision [7,8,11,26,27,31,41,43,46,52,59,62,64–
67,69,71,72,74]. Of these, 10 studies reported issues with
management of supplies [7,11,26,27,62,64,67,69,72,74],
including stock-outs [7,26,62,64,67,69], the use of damaged
or expired RDTs [26,27,64,67] and inappropriate RDTs (i.e.
syphilis RDTs) for HIV testing [72]. Other factors related to
poor management and supervision included testing within the
Figure 1. Study selection process.
RDT: rapid diagnostic test; WB: Western blot; EIA: enzyme immunoassay.
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Table 1. Classification of included studies (n = 64)
Category Study Location
Potential HIV
misdiagnosis and
related factors
Aghokeng et al. [22] Cameroon
Baltazar et al. [23] Mozambique
Baveewo et al. [24] Uganda
Bock et al. [14] South Africa and Zambia
Boeras et al. [25] Zambia and Rwanda
CDC [26] Low- and low–middle-income countries (not specified)
Crucitti et al. [27] Benin, India, South Africa, Uganda and India
da Costa et al. [28] Brazil
Eller et al. [29] Uganda
Fogel et al. [23] Multiple countries in Africa
Galiwango et al. [30] Cameroon
Granade et al. [31] USA
Gray et al. [32] Uganda
Hsiao et al. [33] South Africa
Jentsch et al. [34] South Africa, Tanzania, Uganda and Zambia
Kanal et al. [35] Cambodia
Karugaba et al. [36] Uganda
Khan et al. [37] Swaziland
Klarkowski et al. [38] Central Africa Republic, Congo, DRC, Ethiopia, Haiti, India, Cote d’Ivoire, Myanmar,
Uganda and Zimbabwe
Klarkowski et al. [10] DRC
Kufa et al. [39] South Africa
Learmonth et al. [40] Multi-country study (26 countries)
Manak et al. [16] Nigeria
Maparo et al. [41] Zimbabwe
Martin et al. [42] USA
Masina et al. [43] Malawi
Mayaphi et al. [44] South Africa
Mehra et al. [45] India
Mine et al. [46] Botswana
Nelson et al. [47] Mozambique
Sacks et al. [48] UK
Shanks et al. [11] DRC, Burundi and Ethiopia
Shanks et al. [13] Ethiopia
Shanks et al. [12] Ethiopia
Simoncini et al. [49] Niger
Stetler et al. [50] Honduras
Tchounga et al. [51] Burkina Faso, Cote d’Ivoire and Mali
Wolpaw et al. [52] South Africa
Viani et al. [53] USA and Mexico
Young et al. [54] Mozambique
Focus on misdiagnosis of
HIV-negative
serostatus
Bassett et al. [55] South Africa
Kahemele et al. [56] Tanzania
Matambo et al. [57] Zimbabwe
Olaru et al. [58] Zimbabwe
General quality issues
from sites conducting
HIV testing services
Adebayo et al. [59] Nigeria
Benzaken et al. [60] Brazil
Bile et al. [61] Botswana
Cham et al. [62] 30 countries in Africa
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window period without referring clients for retesting [32,45],
HIV testing performed by undertrained or ineligible staff
[7,31,59,64,72], low levels of retesting to verify diagnosis
before ART initiation [43], poor participation in external quality
assessment (EQA) schemes [62], poor site-level supervision [65]
and poor adherence to standard operating procedures
[7,35,52,59,67,69].
Sixteen studies reported clerical errors [8,11,26,28,
29,31,34,35,45,50,63–65,67,73,75]. Errors included poor
record-keeping [35], data reporting problems, labelling
and transcription mistakes [73] and specimen mix-ups.
Poor record-keeping, according to one study, resulted in
nearly 30% of errors leading to incorrect status [67]. Clerical
errors were not always clearly defined and may not have
always led to misdiagnosis [28].
Fourteen studies reported challenges related to weak
reactive test results, particularly difficulty with interpreta-
tion [8,10,24,27,30,32,36,38,40,42,44,48,62,74]. A study,
which assessed the proficiency of laboratory technicians,
found that specimens with very weak levels of HIV-1/2
antibodies were less accurately reported [40]. In Uganda,
two studies found that the majority of false reactive results
came from weak reactive RDTs [32,36]. A study from the UK
that assessed the visual depiction of false reactive and true
positive readings reported that most false reactive speci-
mens had a fainter test line than true positive specimens
Table 1. (Continued)
Category Study Location
General quality issues Iwe et al. [63] Nigeria
from sites conducting Kalou et al. [64] Uganda and Tanzania
HIV testing services Kitheka et al. [65] Kenya
(Continued) Kyaw et al. [8] Myanmar
Louis et al. [66] Haiti
Lali et al. [67] Uganda
Manyazewal et al. [68] Ethiopia
Mashauri et al. [69] Tanzania
Mwangala et al. [70] Zambia
Ntim et al. [71] Ghana
Ocheng et al. [72] Tanzania
Plate et al. [5] 11 countries in Africa
SEAD [7] South Africa
Sushi et al. [73] India
Tegbaru et al. [74] Ethiopia
DRC: Democratic Republic of Congo.
Table 2. Reported HIV testing errors and factors potentially related to misdiagnosis
Category No. of Studies
Incorrect/suboptimal testing strategy or algorithm (e.g. testing strategies not aligned to the World Health Organization
recommendations, such as a tiebreaker or parallel testing strategies, use of a single RDT to make an HIV-positive
diagnosis)
37
User error (e.g. errors performing RDT or interpreting results, misapplication of buffer, inaccurate reading time and other
human errors)
25
Poor or inadequate management and supervision (e.g. work load stress, staff shortages, lack of training, poor adherence
to testing strategy or testing algorithm, substandard operating procedures, testing in window period)
21
Other factors (e.g. acute infection, cross-reactivity, known HIV status/on ART) 18
Clerical/technical errors (e.g. mislabelling, poor record-keeping and clerical mistakes) 16
Weak reactive test results (e.g. faint or ghost lines appearing on test strip) 14
RDT: rapid diagnostic test; ART: antiretroviral therapy.
Table includes 63 reporting studies. One study (Bile et al. 2017) did not report a specific factor or error related to misdiagnosis. Some studies
reported multiple factors related to poor quality testing and factors that could be related to potential misdiagnosis.
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[48]. Two studies reported incorrect reading of weak reac-
tive bands contributed to the misdiagnosis [10,11].
Eighteen studies reported on several other testing errors
and factors potentially related to misdiagnosis. Nine of
these studies reported cross-reactivity either between
RDTs within an algorithm or with population and individual
characteristics [10,22,24,25,27,32,38,56,60]. One study sug-
gested that cross-reactivity between assays used within an
algorithm resulted in false positive statuses [27]. Another
hypothesized that cross-reactivity may present as weak
reactive lines and thereby cause misdiagnosis [32]. Six
studies [10,11,25,38,56,60] reported potential issues with
RDTs interacting with characteristics of individuals under-
going testing [10,11,38], including having low levels of HIV-
1/2 antibodies due to late stage HIV infection [56,60] and
exposure of assays to adverse environmental conditions
during storage and use [25,38].
Additionally, six studies reported that a proportion of
false negative diagnoses were among people with a
known HIV status who were on ART [14,16,39,44,47,58];
one of these studies was among children on ART retested
using an oral fluid-based HIV RDT [58]. And three studies
reported false negative results were due to patients testing
in the window period [45] or with acute or early infection
[16,44]. For instance, in South Africa, 0.04% (95% CI: 0.0–
0.001) and 0.3% (95% CI: 0.1–0.4) of clients with a false
negative diagnosis using serology tests were later found to
have acute or early HIV infection after retesting with
nucleic acid testing technologies [44].
False positive diagnostic errors and misdiagnosis rates
Thirty studies reported on false positive diagnostic errors
(43 reports; n = 16,777 total positive diagnoses). In general,
error rates were small (median: 3.1%; IQR: 0.4%-5.2%)
with the exception of a few studies where a tiebreaker
test was used to resolve discrepant results [10–
14,23,32,33,37,39,41,44,46,47,75] (Figure 2). Of these, six stu-
dies (eight reports) exclusively among people with HIV enrolled
in care or ART reported that between 0.1% (95% CI: 0–0.3) and
6.6% (95% CI: 4.5–9.6) of people were misdiagnosed (median:
1.6%, IQR: 0.3–4.7%) [10–13,33,37,39,41,47] (Table 3).
In studies reporting false positive diagnoses, nearly all
reported the use of a suboptimal testing strategy [11–
13,33,39,49,75]. Sixteen studies reported the use of a tie-
breaker testing strategy were related to false positive HIV
diagnoses [5,12,13,16,24,25,27,29,30,32,34,36,37,68]. In one
of these studies, 95% (123/129) of false positive statuses
resulted specifically from using a tiebreaker test [32].
Additionally, one study which reported misdiagnosis rates in
Burundi, Democratic Republic of Congo (DRC) and Ethiopia
reported some clients may have been provided an HIV-positive
diagnosis based on a single HIV RDT [11].
False negative diagnostic errors and misdiagnosis rates
Twenty-eight studies reported on false negative diagnoses
(40 reports, total negatives = 55,626) (median: 0.4%, IQR
0–3.9%) (Figure 3) [10,12,13,37,39,47,55–57]. The studies
reporting the highest proportions, for example, Olaru et al.,
which was designed to assess how ART impacts test
performance [58], of false negative diagnoses were exclu-
sively among people with HIV on ART who were retested
using an HIV RDT-based algorithm.
Nearly all studies reporting false negative diagnoses also
reported using a suboptimal testing strategy. Four studies in
South Africa reporting false negative diagnoses reported
that HIV testing was conducted with an algorithm using a
first-line test with high specificity and poorer sensitivity
[14,33,39,55]. According to one of these studies [14],
between 2014 and 2016, the testing algorithm changed
four times in an effort to address the high proportion of
false negative diagnoses resulting from these algorithms.
Clerical and user errors [57], early/acute infection
[16,44,45], presentation late in disease stage [56] and indi-
viduals with known HIV status on ART who sought retesting,
or were retested using oral fluid-based RDTs [58], were also
reported as factors contributing to false negative diagnostic
errors [14,16,39,44,47]. In Zimbabwe, all the reported false
negative diagnoses were among children on ART who were
retested with an oral fluid-based HIV RDT [58]. In South
Africa and Zambia, individuals on ART comprised 44% (26/
59) and 14% (5/38) of false negative diagnoses, respectively
[14]. In Mozambique, 88% (21/24) of all true HIV-positive
clients with a false negative test result were confirmed to
know their HIV status and 62% (13/21) were reportedly on
ART [47]; reasons for retesting in study reportedly included
users misunderstanding the question or hoping to receive
health services and emotional or mental health issues.
Discussion
This review identified and described a number of diagnostic
errors and poor HIV testing practices that may lead to
misdiagnosis. Data on the magnitude of misdiagnosis was
identified but limited, and no study could determine or
quantify the exact cause(s) of misdiagnosis. Although no
studies could determine and quantify the exact cause(s) of
misdiagnosis, several identified the following factors to
have strongly contributed: (1) suboptimal testing strategies,
(2) poor management of supplies, (3) user errors including
difficulty interpreting weak reactive lines and (4) retesting
among people with known HIV status on ART.
No assay is perfect. False reactive and false non-reactive
results are inevitable when using a single RDT and should be
anticipated. However, the risk of misdiagnosis should be very
low when a validated testing algorithm for high (≥5%) or low
(<5%) prevalence settings is used [76]. In this review, we iden-
tified that many studies reporting diagnostic errors - both false
positive and false negative - utilized suboptimal testing strate-
gies which were not aligned to international guidance. Studies
reviewed clearly showed the use of a tiebreaker strategy to
rule-in HIV infection increases the likelihood of false positive
statuses and possible misdiagnosis. This is concerning because
a third of national testing strategies reviewed in 2015 recom-
mended using a tiebreaker testing strategy [9].
In addition to adopting a proven testing strategy, national
or regional validation is critical to determine which RDTs,
and in which order, perform the best as a complete algo-
rithm. As previously reported [38,77–83], tests and
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algorithm performance vary across settings, often due to
cross-reactivity caused by HIV subtypes, co-infections,
comorbidities and possible environmental or population
characteristics. Without validating a testing algorithm at a
country or regional level, it would not be possible to fully
understand the causes of poor performance. Furthermore,
to ensure correct diagnoses, it is important to retest people
diagnosed HIV positive before they enrol in care and ART.
This is a cost-effective approach [84] which is increasingly
critical as more people with HIV are being offered immedi-
ate treatment.
To ensure correct results, all staff providing HIV testing
must be trained, certified and provided ongoing support
and supervision. In several studies, this was not the case,
and untrained and uncertified providers were performing
HIV testing [7,72]. Training, including pre-service, in-service
and periodic refresher training, is important to maintain
and improve the quality of services. Participation in EQA
schemes is another way to monitor performance and
improve testing services. Several studies also reported
user and clerical errors resulted from inadequate support,
demanding workloads, burnout and high levels of stress
[11,62,64,66]. Adequate support and supervision are critical
to reduce stock outs which may contribute to the use of
damaged or expired test kits, incorrect test kits and buffer.
Sites should routinely assess and manage their supplies and
human resource planning to prevent or reduce these
circumstances.
Boeras et al. 2011
Gray et al. 2007
Fogel et al. 2015c
Sacks et al. 2012
Fogel et al. 2015d
Fogel et al. 2015a
Bock et al. 2017 SA
Fogel et al. 2015b
Kanal et al. 2005
Mehra et al. 2014 a
Mine et al. 2015b
Mehra et al. 2014 b
Jentsch et al. 2012
Crucitti et al. 2011
Aghokeng et al.. 2009b
Shanks et al. 2015 (VL)
Shanks et al. 2015
Bock et al. 2017 ZAM
Eller et al. 2007
Klarkowski et al.. 2009
Shanks et al. 2015 (No VL)
Kufa et al. 2017
Shanks et al. 2013 c
Shanks et al. 2013 b
Granade et al. 2004a
Granade et al. 2004b
Viani et al. 2013
Shanks et al. 2013 a
Mine et al. 2015a
Aghokeng et al.. 2009a
Stetler et al. 1997
Baveewo et al. 2012
Manak et al. 2015 (HP)
Baltazar et al. 2014b
Khan et al. 2017
Martin et al. 2011
Hsiao et al. 2017
Maparo et al. 2015
Baltazar et al. 2014a
Nelson et al. 2016
Manak et al. 2015 (LP)
Bassett et al. 2011
Mayaphi et al. 2016
Study
45.95 (31.04, 61.62)
43.73 (38.18, 49.43)
38.64 (25.72, 53.38)
34.62 (19.41, 53.78)
33.33 (21.01, 48.45)
33.33 (9.68, 70.00)
32.78 (27.16, 38.94)
22.22 (6.32, 54.74)
18.18 (5.14, 47.70)
12.20 (5.32, 25.54)
11.11 (4.41, 25.31)
10.26 (4.06, 23.58)
10.24 (7.95, 13.10)
8.70 (3.43, 20.32)
8.26 (4.40, 14.95)
7.84 (3.09, 18.50)
7.31 (4.55, 11.54)
7.02 (5.84, 8.43)
6.58 (3.43, 20.32)
6.58 (4.46, 9.60)
6.54 (3.94, 10.68)
6.00 (2.00, 24.00)
4.81 (3.61, 6.40)
4.70 (2.29, 9.38)
4.21 (1.65, 10.33)
4.11 (1.41, 11.40)
4.00 (0.71, 19.54)
2.56 (0.71, 8.88)
2.43 (1.28, 4.56)
1.96 (0.54, 6.87)
1.61 (0.44, 5.69)
1.38 (0.83, 2.31)
1.16 (0.21, 6.30)
0.78 (0.30, 1.96)
0.55 (0.33, 0.93)
0.54 (0.15, 1.95)
0.32 (0.11, 0.92)
0.28 (0.11, 0.71)
0.19 (0.03, 1.09)
0.09 (0.03, 0.28)
0.00 (0.00, 1.59)
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Figure 2. Rates of false positive diagnostic error rates diagnosis (n = 30 studies, 43 reports).
LP: low prevalence; HP: high prevalence; ZAM: Zambia; VL: visceral Leishmaniasis; Data reported include reports of misdiagnosis of HIV-
positive statuses. False positive diagnoses were reported in 30 studies (43 reports), total positive diagnoses n = 16,777. Kufa et al. 2017
reported proportion misdiagnosed by did not report full sample size. In studies where all participants were known to be HIV positive and/or
on ART at the beginning of the study, the full study population was used as the denominator.
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Table 3. Rates of false positive diagnosis rates among people diagnosed with HIV and/or enrolled in care or antiretroviral therapy
(ART)
Study/author Sample size Total no. of retested No. of false positives Percentage of false positive diagnoses
Klarkowski et al. 2009 365 229 24 6.6
Shanks et al. 2013c 914 54 44 4.8
Shanks et al. 2013b 149 149 7 4.7
Shanks et al. 2013a 78 78 2 2.6
Khan et al. 2017 2533 88 14 0.55
Hsiao et al. 2017 952 37 3 0.3
Maparo et al. 2015 1447 1447 4 0.28
Nelson et al. 2016 3160 3146 3 0.1
Olaru et al. 2017 (blood)
Olaru et al. 2017 (oral)
Khan et al. 2017
Fogel et al. 2015a
Fogel et al. 2015b
Martin et al. 2011
Kufa et al. 2017
Granade et al. 2004b
Granade et al. 2004a
Aghokeng et al.. 2009a
Nelson et al. 2016
Mehra et al. 2014 b
Fogel et al. 2015c
Boeras et al. 2011
Mine et al. 2015a
Bock et al. 2017 SA
Bassett et al. 2011
Mayaphi et al. 2016
Fogel et al. 2015d
Kanal et al. 2005
Baltazar et al. 2014a
Gray et al. 2007
Bock et al. 2017 ZAM
Manak et al. 2015 (LP)
Manak et al. 2015 (HP)
Matambo et al. 2006
Baltazar et al. 2014b
Eller et al. 2007
Mehra et al. 2014 a
Shanks et al. 2015
Sacks et al. 2012
Crucitti et al. 2011
Shanks et al. 2015 (No VL)
Shanks et al. 2015 (VL)
Aghokeng et al.. 2009b
Stetler et al.  1997
Jentsch et al. 2012
Mine et al. 2015b
Viani et al. 2013
Baveewo et al. 2012
Study
100.00 (20.65, 100.00)
100.00 (74.12, 100.00)
82.35 (58.97, 93.81)
18.18 (12.32, 26.00)
13.41 (9.03, 19.48)
12.50 (4.97, 28.07)
8.30 (5.70, 11.90)
7.32 (2.52, 19.43)
6.00 (2.06, 16.22)
5.66 (2.62, 11.00)
3.33 (0.59, 16.67)
2.28 (1.21, 4.28)
1.55 (0.43, 5.48)
1.49 (0.58, 3.76)
1.39 (0.67, 2.83)
1.09 (0.85, 1.42)
1.02 (0.55, 1.86)
0.82 (0.64, 1.07)
0.76 (0.13, 4.20)
0.36 (0.10, 1.31)
0.34 (0.13, 0.88)
0.33 (0.13, 0.84)
0.25 (0.18, 0.34)
0.23 (0.08, 0.69)
0.19 (0.06, 0.55)
0.18 (0.03, 1.03)
0.09 (0.02, 0.49)
0.02 (0.00, 0.11)
0.00 (0.00, 48.99)
0.00 (0.00, 1.80)
0.00 (0.00, 11.35)
0.00 (0.00, 0.07)
0.00 (0.00, 1.97)
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Figure 3. False negative diagnostic error rates (n = 28 studies, 40 reports).
LP: low prevalence; HP: high prevalence; SA: South Africa, discrepant results; ZAM: Zambia, discrepant results; VL: visceral Leishmaniasis;
Data reported includes reports of misdiagnosis of HIV-negative statuses. Misdiagnoses of HIV-negative statuses were reported 28 studies (40
reports), total negative = 55, 626. Kufa et al. 2017 reported proportion misdiagnosed but did not report full sample size information.
Note Olaru et al. was exclusively among people with HIV on ART, accounting for the high rate of false negative diagnoses.
Johnson CC et al. Journal of the International AIDS Society 2017, 20(Suppl 6):21755
http://www.jiasociety.org/index.php/jias/article/view/21755 | http://dx.doi.org/10.7448/IAS.20.7.21755
14
User error interpreting weak reactive lines was a com-
mon challenge which contributed to false positive results.
To address this, specialized training for health workers and
site-level standard operating procedures including the use
of a “second-reader” to validate the correct interpretation
of test results may be needed, as well as work with man-
ufacturers to improve RDTs and instructions on how to
interpret faint lines and weak control lines. Several studies
hypothesized that weak reactive lines may be caused by
other user errors, for example, misapplication of buffer and
reading test results too early and cross-reactivity. Further
investigation into the cause of weak reactive and other
faint lines, and how they can be prevented, is needed.
False negative test results among people with HIV and
on ART were observed and contributed to a substantial
proportion of misdiagnoses [14,16,39,44,47]. While it is
unclear why people on ART would seek retesting, some
reports suggest it may be due to wanting to “check” or
“confirm” one’s HIV status and religious beliefs about
being “cured” [85], as well as misunderstandings and
emotional or mental health issues [47]. It is important
for programmes and users to be aware of the potential
risk of false negative results, as the presence of ART can
lead to confusing test results and could result in indivi-
duals unnecessarily stopping treatment which could have
dire individual and public health implications. As “treat all”
policies are rolled out, it will be increasingly critical for
programmes to address this issue and ensure clients and
health workers are aware that testing individuals on ART is
not recommended [76].
Strengths and limitations
This analysis is the first to bring together a diverse set of
studies with the aim of identifying and describing subopti-
mal HIV testing practices and misdiagnosis. The results
indicate the problem of misdiagnosis deserves attention.
However, there are several limitations to this review.
As with all literature reviews, publication bias may be
an issue and for this topic is inevitable and information
on misdiagnosis is often unreported. This review was also
limited to reports in English and may have missed reports
in other languages. The majority of reports are from
Africa and may not be representative of other geogra-
phies. Because the review was designed to identify
reports of misdiagnosis, it is possible studies reporting
errors and quality of HIV testing may have been missed.
Due to both the paucity and heterogeneity of data, it was
not possible to conduct more quantitative analyses. Studies
included were generally not designed to determine the
exact cause or causes of misdiagnoses, a weakness cited
across research on diagnostic errors [86].
This review focused on human errors and quality system
failures. While we did identify some reports of cross-reac-
tivity [10,22,24,25,27,32,38,56,60], reports did not provide
conclusive information on what exactly caused cross-reac-
tivity. Possible biological factors due to antibodies from
inter-current infections, adverse environmental exposure
to assay components, HIV subtype or shared false cross-
reactivity in RDTs within an algorithm may be issues requir-
ing further investigation.
Acute and early infection did not appear to be a signifi-
cant cause of false negative diagnoses; however, few stu-
dies identified reported on acute infection. Retesting
among HIV-positive individuals taking ART did emerge as a
key factor contributing to a substantial proportion of false
negative diagnostic errors and misdiagnoses. Further
research is needed to understand how ART, as well as the
use of antiretroviral drugs for prevention, for example, pre-
exposure prophylaxis, may impact the performance of HIV
RDTs, as well as how frequently people previously diag-
nosed with HIV and on ART retest.
Conclusions
Our review has identified a number of factors and practices
that may contribute to diagnostic error and HIV misdiagno-
sis. Although no study could fully determine and quantify
the exact cause(s) of misdiagnosis, our review elucidated
four key factors: (1) suboptimal testing strategies, primarily
the use of a tiebreaker testing strategy to rule in HIV
infection, (2) user errors including interpretation of weak
reactive lines, (3) inadequate management and supervision
of testers and (4) retesting among people with HIV on ART.
Most, if not all, are avoidable with appropriate guidelines,
training and supervision. The consequences of misdiag-
noses are serious at an individual and public health level.
With the momentum to scale-up HIV diagnosis and linkage
to ART, a parallel push to improve the quality of HIV testing
services and prevent misdiagnosis is essential.
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